CLAIMS

That Which Is Claimed Is:

1. A compound of formula (I):



I

wherein:

R^1 is alkyl;

w is 0 or 1;

R^{11} is H or C_{1-3}alkyl;

Ring A is selected from the group consisting of cycloalkyl, cycloalkenyl, aryl, 5-13 membered heterocycle and 5-13 membered heteroaryl;

Ring B is selected from the group consisting of cycloalkyl, cycloalkenyl, aryl, 5-13 membered heterocycle and 5-13 membered heteroaryl;

a, b, c, f, g, and h are the same or different and are each independently 0 or 1;

d and j are the same or different and are independently 1 or 2;

each R^2 is the same or different and is independently selected from the group consisting of alkylene, alkenylene and alkynylene;

Y^1 and Y^2 are the same or different and are each independently selected from the group consisting of -O-, $-S(O)_q-$ and $-N(R^5)-$;

q is 0, 1 or 2;

each R^3 and R^4 are the same or different and are each independently selected from the group consisting of H, halo, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, Ph, Het, $-COR^5$, $-CSR^5$, $-CO_2R^5$, -COPh, $-CO_2Ph$, -C(O)Het, $-C(O)NR^5R^6$, $-C(S)NR^5R^6$, $-C(=NR^5)R^6$, $-C(=NR^5)NR^5R^6$, $-CR^5=N-OR^6$, $-OR^5$, $-OCOR^5$, $-S(O)_pR^5$, $-S(O)_2OH$, $-S(O)_pNR^5R^6$, $-NR^5R^6$, $-NR^5COR^6$, $-NR^5CO_2R^6$, $-NR^5SO_2R^6$, $-NO_2$, -CN, -SCN and $-N_3$;

each p is the same or different and is 0, 1 or 2;

m and n are the same or different and are each independently 0, 1, 2, 3, 4 or 5;

each R^5 and each R^6 are the same or different and are each independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl and cycloalkenyl;

Ph is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, alkyl, $-CO_2R^5$, $-OR^5$, $-SO_2R^5$, $-SO_2NR^5R^6$, $-NR^5R^6$, $-R^2-(NR^5R^6)CO_2R^5$, Het, $-R^2$-Het, -CN and $-N_3$; and

Het is a monocyclic 5-6 membered heterocycle or heteroaryl group containing 1, 2 or 3 heteroatoms selected from the group consisting of N, O and S optionally substituted by one or more substituents selected from the group consisting of halo, alkyl, $-CO_2R^5$, $-C(O)NR^5R^6$, $-OR^5$, $-SO_2R^5$, $-SO_2NR^5R^6$, $-NR^5R^6$, oxo, -CN and $-N_3$;

or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof.

2. The compound according to claim 1, wherein R^1 is methyl.

3. The compound according to any of claims 1-2, wherein Ring A is selected from the group consisting of aryl and 5-13 membered heteroaryl.

4. The compound according to any of claims 1-2, wherein Ring A is phenyl.

5. The compound according to any of claims 1-4, wherein Ring B is selected from the group consisting of phenyl, pyridine and pyrimidine.

6. The compound according to any of claims 1-4, wherein Ring B is phenyl.

7. The compound according to any of claims 1-6, wherein each R^2 is the same or different and is independently selected from the group consisting of alkylene and alkenylene.

8. The compound according to any of claims 1-7, wherein b is 0.

9. The compound according to any of claims 1-7, wherein b is 1 and Y^1 is selected from the group consisting of -O- and -N(R^5)-.

10. The compound according to any of claims 1-9, wherein g is 0.

11. The compound according to any of claims 1-9, wherein g is 1 and Y^2 is -O-.

12. The compound according to any of claims 1-11, wherein d is 1.

13. The compound according to any of claims 1-12, wherein j is 1.

14. The compound according to any of claims 1-13, wherein each R^3 is the same or different and is independently selected from the group consisting of H, halo, alkyl, alkenyl, cycloalkyl, Ph, Het, $-COR^5$, $-CO_2R^5$, -COPh, $-C(O)NR^5R^6$, $-OR^5$, $-S(O)_pR^5$, $-S(O)_pNR^5R^6$, $-NR^5R^6$, $-NO_2$, -CN and $-N_3$.

15. The compound according to any of claims 1-13, wherein d is 1 and R^3 is selected from the group consisting of H, halo, alkyl, Ph, $-COR^5$, $-CO_2R^5$, -COPh, $-C(O)NR^5R^6$, $-OR^5$, $-NR^5R^6$, $-NO_2$ and -CN.

16. The compound according to any of claims 1-15, wherein each R^4 is the same or different and is independently selected from the group consisting of H, halo, alkyl, alkenyl, cycloalkyl, Ph, Het, $-COR^5$, $-CO_2R^5$, $-C(O)NR^5R^6$, $-OR^5$, $-S(O)_pR^5$, $-S(O)_2OH$, $-S(O)_pNR^5R^6$, $-NR^5R^6$, $-NR^5COR^6$, $-NO_2$ and -CN.

17. The compound according to any of claims 1-15, wherein j is 1 and R^4 is selected from the group consisting of H, halo, alkyl, $-COR^5$, $-CO_2R^5$, $-C(O)NR^5R^6$, $-OR^5$, $-S(O)_pR^5$, $-S(O)_2OH$, $-S(O)_pNR^5R^6$ and $-NO_2$.

18. The compound according to any of claims 1-17, wherein m is 0, 1, 2 or 3.

19. The compound according to any of claims 1-18, wherein n is 1, 2, or 3.

20. The compound according to any of claims 1-19, wherein each R^5 and each R^6 are the same or different and are each independently selected from the group consisting of H, alkyl, alkenyl and cycloalkyl.

21. The compound according to any of claims 1-19, wherein each R^5 and each R^6 are the same or different and are each independently selected from the group consisting of H and alkyl.

22. A compound selected from the group consisting of:

5-Methyl-7-phenyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

5-Methyl-7-(2-nitrophenyl)-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-f][1,2,4]triazin-2-amine;

7-(2-Bromophenyl)-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

7-(4-Fluorophenyl)-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

5-Methyl-7-[3-(trifluoromethyl)phenyl]-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

2,2-Dimethyl-*N*-(2-{5-methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}phenyl)propanamide;

2,2,2-Trifluoro-*N*-(2-{5-methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}phenyl)acetamide;

3-{5-Methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}benzonitrile;

7-(3-Bromophenyl)-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

7-(3-Bromothien-2-yl)-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

7-(5-Bromopyridin-3-yl)-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo-[5,1-*f*][1,2,4]triazin-2-amine;

Methyl 3-{5-methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}benzoate;

7-(5-Bromothien-2-yl)-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

7-(3-Bromophenyl)-*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-methylimidazo[5,1-*f*][1,2,4]triazin-2-amine;

7-(3-Bromophenyl)-*N*-(3-chloro-4-morpholin-4-ylphenyl)-5-methylimidazo[5,1-*f*][1,2,4]triazin-2-amine;

3-{5-Methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}benzamide;

(2*E*)-3-(3-{5-Methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}phenyl)prop-2-enamide;

5-Methyl-*N*-(4-nitrophenyl)-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;

2-{3-[(5-Methyl-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-yl)amino]phenyl}ethanol;

4-[(5-Methyl-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-yl)amino]benzene-sulfonamide;

7-(2-Methoxyphenyl)-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

2-{5-Methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}phenol;

2-{5-Methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}phenyl acetate;

5-Methyl-7-[4-(trifluoromethyl)phenyl]-*N*-(3,4,5-trimethoxyphenyl)-imidazo[5,1-*f*][1,2,4]triazin-2-amine;

N-Methyl-*N*-{4-[(5-methyl-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-yl)amino]phenyl}urea;

5-Methyl-7-phenyl-*N*-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-amine;

(3-{5-Methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}phenyl)(phenyl)methanone;

7-(1,3-Benzodioxol-5-yl)-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo-[5,1-*f*][1,2,4]triazin-2-amine;

Methyl 4-{5-methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}benzoate;

5-Methyl-7-(3-phenoxyphenyl)-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

7-(3-Aminophenyl)-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

7-(1*H*-Indol-2-yl)-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

5-Methyl-7-(5-nitro-1*H*-pyrrol-2-yl)-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

5-Methyl-7-(1-methyl-1*H*-pyrrol-2-yl)-*N*-(3,4,5-trimethoxyphenyl)-imidazo[5,1-*f*][1,2,4]triazin-2-amine;

5-Methyl-7-(1-methyl-1*H*-indol-3-yl)-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

7-(3-Furyl)-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

7-(1*H*-Indol-5-yl)-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

2-[(2-{5-Methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}phenyl)thio]benzonitrile;

5-Methyl-7-(2-{[3-(trifluoromethyl)phenyl]amino}phenyl)-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

5-Methyl-7-quinolin-8-yl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

3-({5-Methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-yl}amino)benzenesulfonamide;

N-Methyl-*N*-[4-({5-methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-yl}amino)phenyl]urea;

N-[4-Methoxy-3-({5-methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-yl}amino)phenyl]acetamide;

2-[3-({5-Methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-yl}amino)phenyl]ethanol;

4-({5-Methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-yl}amino)benzenesulfonamide;

N-[4-({5-Methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-yl}amino)phenyl]acetamide;

N-[3-({5-Methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-yl}amino)phenyl]acetamide;

tert-Butyl 3-({5-methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-yl}amino)benzylcarbamate;

4-({5-Methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-yl}amino)phenol;

5-Methyl-*N*-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-7-[3-(trifluoromethyl)phenyl]-imidazo[5,1-*f*][1,2,4]triazin-2-amine;

N-(5-Fluoro-2-methoxyphenyl)-5-methyl-7-[3-(trifluoromethyl)phenyl]-imidazo[5,1-*f*][1,2,4]triazin-2-amine;

N-{2-[4-Methoxy-3-({5-methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-yl}amino)phenyl]ethyl}acetamide;

N-[5-(2-Aminoethyl)-2-methoxyphenyl]-5-methyl-7-[3-(trifluoromethyl)-phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-amine;

N-(2,4-Dimethoxyphenyl)-5-methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-amine;

N-(2,5-Dimethoxyphenyl)-5-methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-amine;

Ethyl 5-({5-methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-yl}amino)nicotinate;

2-{3-[(5-Methyl-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-yl)amino]phenyl}-ethanesulfonic acid;

5-Methyl-7-[3-(1*H*-pyrazol-4-ylethynyl)phenyl]-*N*-(3,4,5-trimethoxyphenyl)-imidazo[5,1-*f*][1,2,4]triazin-2-amine;

3'-{5-Methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}-1,1'-biphenyl-3-carboxylic acid;

2-Amino-3-(3'-{5-methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo-[5,1-*f*][1,2,4]triazin-7-yl}-1,1'-biphenyl-4-yl)propanoic acid;

5-Methyl-7-[2'-(trifluoromethyl)-1,1'-biphenyl-3-yl]-*N*-(3,4,5-trimethoxyphenyl)-imidazo[5,1-*f*][1,2,4]triazin-2-amine;

(2*Z*)-3-(3-{5-Methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}phenyl)-3-phenylprop-2-enamide;

7-(3-{[5-(Ethylsulfonyl)-2-methoxyphenyl]amino}phenyl)-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

5-Methyl-7-(3-{[4-(1*H*-1,2,4-triazol-1-ylmethyl)phenyl]amino}phenyl)-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

7-(3-{[4-(1*H*-imidazol-1-yl)phenyl]amino}phenyl)-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

7-{3-[(3-Chloro-4-morpholin-4-ylphenyl)amino]phenyl}-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

N,*N*-Dimethyl-1-{3-[(3-{5-methyl-2-[(3,4,5-trimethoxyphenyl)amino] imidazo[5,1-*f*][1,2,4]triazin-7-yl}phenyl)amino]phenyl}-methanesulfonamide;

5-Methyl-7-[3-({4-[(4-methylpiperazin-1-yl)methyl]phenyl}-amino)phenyl]-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

N-Cyclopropyl-3-[(3-{5-methyl-2-[(3,4,5-trimethoxyphenyl)amino] imidazo[5,1-*f*][1,2,4]triazin-7-yl}phenyl)amino]benzenesulfonamide;

7-(5-Bromo-2-thienyl)-5-methyl-*N*-[4-(methyloxy)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-amine;

7-(3-Bromo-2-thienyl)-5-methyl-*N*-[4-(methyloxy)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-amine;

5-Methyl-*N*-[4-(methyloxy)phenyl]-7-(tetrahydro-2H-pyran-4-yl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

5-Methyl-7-[2-(methyloxy)phenyl]-*N*-[4-(methyloxy)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-amine;

5-Methyl-7-[3-(methyloxy)phenyl]-*N*-[4-(methyloxy)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-amine;

7-(2-Chlorophenyl)-5-methyl-*N*-[4-(methyloxy)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-amine;

5-Methyl-7-(1-methyl-1H-indol-3-yl)-*N*-[4-(methyloxy)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-amine;

5-Methyl-*N*-[4-(methyloxy)phenyl]-7-(1-phenylethyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

5-Methyl-7-(1-methyl-1H-indol-2-yl)-*N*-[4-(methyloxy)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-amine;

5-Methyl-*N*-[4-(methyloxy)phenyl]-7-(3-thienyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

7-(3-Furanyl)-5-methyl-*N*-[4-(methyloxy)phenyl]imidazo-[5,1-*f*][1,2,4]triazin-2-amine;

7-(2-Furanyl)-5-methyl-*N*-[4-(methyloxy)phenyl]imidazo-[5,1-*f*][1,2,4]triazin-2-amine;

7-(4-Fluorophenyl)-5-methyl-*N*-[4-(methyloxy)phenyl]-imidazo[5,1-*f*][1,2,4]triazin-2-amine;

5-Methyl-*N*-[4-(methyloxy)phenyl]-7-(2-thienyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

7-Cyclopropyl-5-methyl-*N*-[4-(methyloxy)phenyl]-imidazo[5,1-*f*][1,2,4]triazin-2-amine;

7-Cyclohexyl-5-methyl-*N*-[4-(methyloxy)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-amine;

7-(2-FluorophenylFluorophenyl)-5-methyl-*N*-[4-(methyloxy)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-amine;

5-Methyl-N,7-bis[4-(methyloxy)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-amine;

5-Methyl-*N*-[4-(methyloxy)phenyl]-7-(phenylmethyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

7-(3-Fluorophenyl)-5-methyl-*N*-[4-(methyloxy)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-amine;

7-Cyclohexyl-5-methyl-*N*-[3,4,5-tris(methyloxy)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-amine;

7-(Cyclohexylmethyl)-5-methyl-*N*-[4-(methyloxy)phenyl]-imidazo[5,1-*f*][1,2,4]triazin-2-amine;

N-[3,4-Bis(methyloxy)phenyl]-5-methyl-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;

N-[3,5-Bis(methyloxy)phenyl]-5-methyl-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;

N-{4-[(5-Methyl-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-yl)amino]phenyl}acetamide;

5-Methyl-*N*-[4-(methylthio)phenyl]-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;

N-(4-{[2-(Dimethylamino)ethyl]oxy}phenyl)-5-methyl-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;

5-Methyl-7-phenyl-*N*-(4-{[2-(1-piperidinyl)ethyl]-oxy}phenyl)-imidazo[5,1-*f*][1,2,4]triazin-2-amine;

N-(3-{[2-(Dimethylamino)ethyl]oxy}phenyl)-5-methyl-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;

N-(1-Acetyl-2,3-dihydro-1H-indol-5-yl)-5-methyl-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;

N-Cyclohexyl-5-methyl-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;

5-Methyl-7-phenyl-*N*-(tetrahydro-2H-pyran-4-yl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

5-Methyl-*N*-(4-{[2-(4-morpholinyl)ethyl]oxy}phenyl)-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;

5-Methyl-*N*-(3-{[2-(4-morpholinyl)ethyl]oxy}phenyl)-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;

5-Methyl-*N*-[4-(methyloxy)phenyl]-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;

5-Methyl-*N*,7-diphenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;

5-Methyl-*N*-[3-(methyloxy)phenyl]-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;

and pharmaceutically acceptable salts, solvates and physiologically functional derivatives thereof.

23. A pharmaceutical composition comprising a compound according to any of claims 1-22.

24. The pharmaceutical composition according to claim 23 further comprising a pharmaceutically acceptable carrier, diluent or excipient.

25. The pharmaceutical composition according to any of claims 23-24 further comprising a chemotherapeutic agent.

26. A method for the treatment of a condition mediated by PLK in an animal in need thereof, said method comprising administering to the animal a therapeutically effective amount of a compound according to any of claims 1-22.

27. A method for the treatment of a neoplasm susceptible to PLK in an animal in need thereof, said method comprising administering to the animal a therapeutically effective amount of a compound according to any of claims 1-22.

28. The method according to claim 27, wherein said neoplasm is selected from the group consisting of breast cancer, colon cancer, lung cancer, prostate cancer, lymphoma, leukemia, endometrial cancer, melanoma, ovarian cancer, gastric carcinoma, pancreatic cancer, squamous carcinoma, carcinoma of the head and neck, and esophageal carcinoma.

29. A method for the treatment of a PLK-mediated condition characterized by inappropriate cellular proliferation in an animal in need thereof, said method comprising administering to the animal a therapeutically effective amount of a compound according to any of claims 1-22.

30. A method for inhibiting proliferation of a cell, said method comprising contacting the cell with an amount of a compound according to any of claims 1-22 sufficient to inhibit proliferation of the cell, wherein said compound inhibits PLK.

31. A method for inhibiting mitosis in a cell, said method comprising administering to the cell an amount of a compound according to any of claims 1-22 sufficient to inhibit mitosis in the cell, wherein said compound inhibits PLK.

32. A process for preparing a compound according to any of claims 1-22, said process comprising reacting a compound of formula (X):



X

with a cyclization reagent.

33. A process for preparing a compound according to any of claims 1-22, said process comprising reacting the compound of formula (XIII):



XIII

with a compound of formula (VI):



VI

34. A process for preparing a compound according to any of claims 1-22 wherein:

Ring A is selected from the group consisting of cycloalkyl, aryl, 5-13 membered heterocycle and 5-13 membered heteroaryl;

each R^2 is the same or different and is alkylene;

each R^3 and R^4 are the same or different and are each independently selected from the group consisting of H, halo, alkyl, alkenyl, alkynyl, cycloalkyl, Ph, Het, $-OR^5$, $-S(O)_pR^5$, $-S(O)_2OH$, $-S(O)_pNR^5R^6$, $-NR^5R^6$ and $-NR^5SO_2R^6$;

each R^5 and each R^6 are the same or different and are each independently selected from the group consisting of H, alkyl and cycloalkyl;

Ph is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, alkyl, $-OR^5$, $-SO_2R^5$, $-SO_2NR^5R^6$, $-NR^5R^6$, Het, and $-R^2$-Het; and

Het is a monocyclic 5-6 membered heterocycle or heteroaryl group containing 1, 2 or 3 heteroatoms selected from the group consisting of N, O and S optionally substituted by one or more substituents selected from the group consisting of halo, alkyl, $-OR^5$, $-SO_2R^5$, $-SO_2NR^5R^6$, $-NR^5R^6$ and oxo; and

said process comprising coupling a compound of formula (XVIII):



XVIII

with a compound of formula (XIX):



XIX

wherein X is Cl, Br, I or triflate.

35. The process according to any of claims 32-34, said process further comprising the step of converting a compound of formula (I) to a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof.

36. The process according to any of claims 32-35 fur
step of converting a compound of formula (I) or a pharm
acceptable salt, solvate or physiologically functional der
another compound of formula (I) or a pharmaceutically a
solvate or physiologically functional derivative thereof.

37. A compound according to any of Claims 1-22 for

38. A compound according to any of Claims 1-22 for
of a condition mediated by PLK in an animal.

39. A compound according to any of claims 1-22 for
a neoplasm susceptible to PLK in an animal.

40. A compound according to any of claims 1-22 for
a PLK-mediated condition characterized by inappropria
in an animal.

41. A compound according to any of claims 1-22 for
proliferation of a cell, wherein said compound inhibits P

42. A compound according to any of claims 1-22 for
mitosis in a cell, wherein said compound inhibits PLK.

43. The use of a compound according to any of clain
preparation of a medicament for the treatment of condit
in an animal.

44. The use of a compound according to any of clair
preparation of a medicament for the treatment of a neo
PLK in an animal.

45. The use of a compound according to any of claims 1-22 for the preparation of a medicament for the treatment of a PLK-mediated condition characterized by inappropriate cellular proliferation.

46. A pharmaceutical composition comprising a compound according to any of claims 1-22 for use in the treatment of a neoplasm susceptible to PLK in an animal.